BriaCell Therapeutics Corp. (TSE:BCT – Get Free Report)’s share price traded down 4% on Friday . The company traded as low as C$4.26 and last traded at C$4.31. 14,972 shares were traded during trading, a decline of 35% from the average session volume of 23,139 shares. The stock had previously closed at C$4.49.
BriaCell Therapeutics Trading Down 4.0%
The company has a market cap of C$37.50 million, a PE ratio of -0.30 and a beta of 2.06. The business has a 50 day simple moving average of C$5.38 and a two-hundred day simple moving average of C$7.59.
About BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.
Read More
- Five stocks we like better than BriaCell Therapeutics
- 3 Stocks Under $20 to Buy Before a Broader Market Rally
- Petco Faces Tough Competition, But Momentum Is Building
- The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It
- 3 ETFs For the Coming Genomics Revolution
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
